Stockscreener 앱 받기
1.41%
Pfizer Inc 주식(PFE)의 최신 뉴스
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - Business Wire
Pfizer stock slips in premarket as tariff jitters hit futures and weight-loss race resurfaces - Bez Kabli
Telescope Innovations Installs Second Self-Driving Lab at Pfizer - TMX Newsfile
Pfizer’s Comirnaty Update: What U.S. Patients Really Need to Know Now - AD HOC NEWS
Assessing Pfizer (PFE) Valuation As Investors Revisit Mixed Returns And Oncology Growth Prospects - simplywall.st
Massive News: Pfizer's 6% Dividend Could Be Safer Than You Think - Nasdaq
Stevens Capital Management LP Makes New Investment in Pfizer Inc. $PFE - MarketBeat
Pfizer Ltd: India Arm Pops on Strong Q3—But Is It a Buy for US Investors? - AD HOC NEWS
Pfizer: A Risky 6.3% Yield For Income-Oriented Investors - Seeking Alpha
Is Pfizer Stock an Underrated Healthcare Investment Play? - The Globe and Mail
Pfizer (PFE) Among Pharma Giants Securing Tariff Exemption - GuruFocus
Pfizer (PFE) Stock Falls to $26.59 as Barclays Sets $25 Target — Can Oncology Growth Offset Patent Loss Risks? - Swikblog
Barclays Initiates Coverage of Pfizer (PFE) with Underweight Recommendation - Nasdaq
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026? - The Globe and Mail
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday - Benzinga
Moderna Faces Lawsuit From BioNTech Over Next-Generation COVID-19 Shot - Benzinga
Barclays Initiates Coverage on Pfizer (PFE) with Underweight Rat - GuruFocus
Jupiter Asset Management Ltd. Raises Holdings in Pfizer Inc. $PFE - MarketBeat
Barclays Initiates Coverage on Pfizer With Underweight Rating - marketscreener.com
Barclays initiates Pfizer stock with underweight on patent losses - Investing.com
Moderna faces COVID vaccine patent suit from BioNTech (MRNA) - Seeking Alpha
Glucagon-like Peptide 1 (GLP-1) Market Report 2026-2035: Market to Reach $33.26 Billion by 2030 - GlobeNewswire Inc.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Lowers Position in Pfizer Inc. $PFE - MarketBeat
Nicotine Gum Market Analysis Report 2026-2035: A $2.55 Billion Market by 2030 with Pfizer, GlaxoSmithKline, Haleon, Perrigo Co, and Johnson & Johnson Leading - Yahoo Finance
Pfizer Inc (PFE) Announces Positive Results from BREAKWATER Trial - Insider Monkey
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash? - Nasdaq
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades) - Seeking Alpha
Pfizer (NYSE:PFE) Shares Down 1.8%Should You Sell? - MarketBeat
Pfizer's BRAFTOVI Trial Win Adds Weight To Undervalued Oncology Story - simplywall.st
Where is Pfizer Inc. (PFE) headed? - MSN
Muscle Invasive Bladder Cancer Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, Protara Therapeutics, Binhui Biopharmaceutical - Barchart.com
Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer - FinancialContent
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure - TradingView
Where is Pfizer Inc. (PFE) Headed? - Insider Monkey
Pzena Investment Management LLC Boosts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Seagen Is Gone From Nasdaq—Why the Pfizer Deal Still Matters to You - AD HOC NEWS
Axxcess Wealth Management LLC Boosts Stake in Pfizer Inc. $PFE - MarketBeat
First National Bank of Omaha Purchases New Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Ponders Viagra Lessons to Chart First Obesity Drug Launch - Bloomberg.com
Pfizer Just Flipped the Script: Why This Pharma Giant Matters to Your Wallet Now - AD HOC NEWS
Neuropsychiatry Market Is Going to Boom | Pfizer Inc. • Bristol-Myers Squibb • AstraZeneca - openPR.com
Pfizer (PFE) Experiences Mixed Options Sentiment Amid Downgrade - GuruFocus
Is There 25% Downside For Pfizer Stock? - Forbes
Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study - TipRanks
Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game - Seeking Alpha
Pfizer Colorectal Cancer Trial Win Adds Weight To Oncology Turnaround Story - Yahoo Finance
Pfizer (PFE) Valuation Check After Recent Share Price Rebound And Mixed Earnings Signals - Yahoo Finance Singapore
Sleep Aids Market 2026-2035 Top Key Playres: Pfizer (US), - openPR.com
Essex Financial Services Inc. Trims Stock Holdings in Pfizer Inc. $PFE - MarketBeat
CenterBook Partners LP Has $12.65 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Advisors Capital Management LLC Purchases 260,742 Shares of Pfizer Inc. $PFE - MarketBeat
NEOS Investment Management LLC Purchases 223,163 Shares of Pfizer Inc. $PFE - MarketBeat
Skandinaviska Enskilda Banken AB publ Trims Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer’s BRAFTOVI Data Adds New Dimension To Oncology Growth Story - simplywall.st
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer - Business Wire
Pfizer: The Rebound Looks Unsustainable (NYSE:PFE) - Seeking Alpha
Pfizer’s Braftovi Scores Again In Confirmatory Colorectal Cancer Trial - Citeline News & Insights
Mubadala Investment Co PJSC reports share stake in Pfizer, AbbVie, dissolves in Merck, Dell - marketscreener.com
Mubadala Investment Co Pjsc Reports Share Stake In Pfizer, Abbvie, Dissolves in Merck, Dell - TradingView
How Is The Market Feeling About Pfizer Inc? - Benzinga
Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer TrialPfizer (NYSE:PFE) - Benzinga
Pfizer's (PFE) Braftovi Shows Promise in Colorectal Cancer Trial - GuruFocus
Pfizer posts trial win for cancer therapy Braftovi (PFE:NYSE) - Seeking Alpha
Pfizer (PFE) Reports Positive Results from BREAKWATER Trial in m - GuruFocus
Pfizer Trial Updates Test Investor Views On Pipeline And Valuation - Yahoo Finance
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Britannica
Pfizer Inc. $PFE is PARK CIRCLE Co's 10th Largest Position - MarketBeat
Pfizer's Braftovi regimen improves progression-free survival in metastatic colorectal cancer - marketscreener.com
Rothschild & Co Redburn Adjusts Price Target on Pfizer to $25 From $23, Maintains Neutral Rating - marketscreener.com
M&G PLC Lowers Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Shell Asset Management Co. Has $1.03 Million Holdings in Pfizer Inc. $PFE - MarketBeat
15.89%
1.58%
자본화:
|
볼륨(24시간):